GoldenGolden
Advanced Search
Antengene

Antengene

Antengene is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines.

Antengene is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. Antengene has established a pipeline of 12 drug assets focused on oncology, including two late-stage clinical assets, four early-stage clinical assets. In addition, leveraging R&D capabilities, Antengene are internally developing six pre-clinical stage assets, which focus on novel targets or MoAs and hence have potential to address significant unmet medical needs. More importantly, these assets target the key oncogenic pathways and are highly synergistic to our pipeline assets.

Timeline

May 28, 2021
Antengene announces first patient dosed in Phase I/II trial of eltanexor for the treatment of myelodysplastic syndrome.
July 20, 2020
Antengene raises a $97,000,000 series C round.
January 2, 2019
Antengene raises a $120,000,000 series B round.
January 2, 2019
Antengene raises a $120,000,000 series B round from Boyu Capital.
January 2019
Antengene raises a $120,000,000 series B round from Boyu Capital, Celgene, FountainVest Partners, Qiming Venture Partners, TF Capital, Taikang Life Insurance and WuXi AppTec Corporate Venture fund.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Antengene Corporation Limited
June 9, 2021
www.prnewswire.com:443
/PRNewswire/ -- Antengene's Partner, Karyopharm Therapeutics Inc. (Nasdaq: KPTI), announced updated data of eltanexor for the treatment of patients with...
BioSpace
May 25, 2021
BioSpace
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced the appointment of Ms. Kathryn Gregory as Vice President and Head of Corporate Business Development
May 17, 2021
BioSpace
Antengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708 (ATG-037) - read this article along with other careers information, tips and advice on BioSpace
Antengene Corporation Limited
April 29, 2021
www.prnewswire.com:443
/PRNewswire/ -- With the official release and implementation of the Overall Plan for the Construction of Hainan Free Trade Port, patient can now access global...
FinSMEs
November 23, 2020
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Eudora Wang
November 20, 2020
DealStreetAsia
Fidelity and GIC, were among the cornerstone investors in the IPO.
Qiming Venture Partners
November 20, 2020
www.prnewswire.com:443
/PRNewswire/ -- Qiming's portfolio company Antengene (SEHK: 6996) officially listed on the Main Board of The Stock Exchange of Hong Kong Limited today. The...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.